Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

906 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR. Kaiser PK, et al. Among authors: Brown DM. Am J Ophthalmol. 2007 Dec;144(6):850-857. doi: 10.1016/j.ajo.2007.08.012. Epub 2007 Oct 22. Am J Ophthalmol. 2007. PMID: 17949673 Clinical Trial.
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Brown DM, et al. Ophthalmology. 2010 Jun;117(6):1124-1133.e1. doi: 10.1016/j.ophtha.2010.02.022. Epub 2010 Apr 9. Ophthalmology. 2010. PMID: 20381871 Clinical Trial.
Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.
Chen E, Brown DM, Wong TP, Benz MS, Kegley E, Cox J, Fish RH, Kim RY. Chen E, et al. Among authors: Brown DM. Clin Ophthalmol. 2010 Oct 5;4:1073-9. doi: 10.2147/OPTH.S13969. Clin Ophthalmol. 2010. PMID: 20957143 Free PMC article.
906 results
Jump to page
Feedback